HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

BACKGROUND: Although clear cell renal cell carcinoma (ccRCC) is well known as a highly immunogenic tumor, only a small subset of patients could benefit from current immunotherapy, which might be due to the heterogeneity of immune microenvironment in ccRCC. So, it is meaningful to explore novel immun...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Zhou, Qiang-Hua, Li, Kai-Wen, Chen, Xu, He, Hai-Xia, Peng, Sheng-Meng, Peng, Shi-Rong, Wang, Qiong, Li, Ze-An, Tao, Yi-Ran, Cai, Wen-Li, Liu, Ran-Yi, Huang, Hai
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Immunotherapy Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057441/
https://ncbi.nlm.nih.gov/pubmed/31959726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados